CNM-Au8 in Amyotrophic Lateral Sclerosis

Overview of attention for article published in JAMA: Journal of the American Medical Association, February 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 8 news outlets
blogs: 4 blogs
twitter: 10 X users
facebook: 3 Facebook pages

video: 1 YouTube creator
bluesky: 4 Bluesky users
podcasts: 2 podcasts

Readers on

mendeley: 30 Mendeley

So far, Altmetric has seen 13 X posts from 10 X users, with an upper bound of 603,796 followers.

CNM-Au8, an oral suspension of catalytically active gold particles, did not improve the primary efficacy outcome of amyotrophic lateral sclerosis disease progression. https://t.co/hTRmdfZEgH

RT @MarkQuarter: @tabibito250 "Conclusions and relevance: No benefit of CNM-Au8 on ALS disease progression was observed at 24 weeks" https…

@tabibito250 "Conclusions and relevance: No benefit of CNM-Au8 on ALS disease progression was observed at 24 weeks" https://t.co/acgmEF9rgi

RT @tabibito250: CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial | Amyotrophic Lateral Sclerosis | JAMA | JAMA Netw…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 9 additional X posts.